Publication | Open Access
Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a randomized, open-label, phase II trial
10
Citations
0
References
2019
Year
MedicineMelanoma3-Year Landmark AnalysisImmune Checkpoint InhibitorTalimogene LaherparepvecDermatologyCancer TreatmentImmunotherapyOncologyRadiation OncologyAdvanced MelanomaTumor MicroenvironmentTumor BiologySkin Cancer
No additional data available for this publication yet. Check back later!